US FDA reverses course on Regenxbio’s rare-disease gene therapy, backs accelerated approval bid

This is a summary. Read the complete story at Investing.com below.

Related Stories

stocksabout 1 hour ago

European shares rise on banking boost

Investing.com

stocksabout 1 hour ago

Genmab shares rise 4% on J&J cancer drug FDA approval

Investing.com

stocksabout 1 hour ago

Outokumpu shares fall 5% after JPMorgan downgrade

Investing.com